[
  {
    "ts": null,
    "headline": "GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal",
    "summary": "Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.",
    "url": "https://finnhub.io/api/news?id=2e0ed80876e5ed48844cb4eaa011658605b6b4b5e64d9b8d6f59946909e076c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765893180,
      "headline": "GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal",
      "id": 137806411,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.",
      "url": "https://finnhub.io/api/news?id=2e0ed80876e5ed48844cb4eaa011658605b6b4b5e64d9b8d6f59946909e076c1"
    }
  },
  {
    "ts": null,
    "headline": "FDA ‘proactively’ hands J&J a voucher; Pfizer issues 2026 forecasts",
    "summary": "The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new cell therapy player emerged and Sanofi cut deals with two startups.",
    "url": "https://finnhub.io/api/news?id=44a5c05615b5b31406cf0b8b992e99b544705e0613c769fed6df5ae261ae067f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765880400,
      "headline": "FDA ‘proactively’ hands J&J a voucher; Pfizer issues 2026 forecasts",
      "id": 137806044,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new cell therapy player emerged and Sanofi cut deals with two startups.",
      "url": "https://finnhub.io/api/news?id=44a5c05615b5b31406cf0b8b992e99b544705e0613c769fed6df5ae261ae067f"
    }
  }
]